Gt Biopharma Stock Price Patterns
| GTBP Stock | USD 0.46 0.03 5.55% |
Momentum 33
Sell Stretched
Oversold | Overbought |
EPS Estimate Next Quarter (0.21) | EPS Estimate Current Year (1.66) | EPS Estimate Next Year (0.70) | Wall Street Target Price 8 | EPS Estimate Current Quarter (0.38) |
Using GT Biopharma hype-based prediction, you can estimate the value of GT Biopharma from the perspective of GT Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in GT Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying GTBP because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
GT Biopharma after-hype prediction price | USD 0.45 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out GT Biopharma Basic Forecasting Models to cross-verify your projections. GT Biopharma After-Hype Price Density Analysis
As far as predicting the price of GT Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in GT Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of GT Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
GT Biopharma Estimiated After-Hype Price Volatility
In the context of predicting GT Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on GT Biopharma's historical news coverage. GT Biopharma's after-hype downside and upside margins for the prediction period are 0.02 and 7.11, respectively. We have considered GT Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
GT Biopharma is dangerous at this time. Analysis and calculation of next after-hype price of GT Biopharma is based on 3 months time horizon.
GT Biopharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as GT Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GT Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with GT Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.54 | 6.65 | 0.01 | 0.04 | 9 Events / Month | 5 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.46 | 0.45 | 2.30 |
|
GT Biopharma Hype Timeline
GT Biopharma is currently traded for 0.46. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.04. GTBP is forecasted to decline in value after the next headline, with the price expected to drop to 0.45. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -2.3%, whereas the daily expected return is currently at -0.54%. The volatility of related hype on GT Biopharma is about 9665.7%, with the expected price after the next announcement by competition of 0.42. The book value of the company was currently reported as 0.5. The company recorded a loss per share of 3.5. GT Biopharma last dividend was issued on the 21st of August 2017. The entity had 1:30 split on the 5th of February 2024. Given the investment horizon of 90 days the next forecasted press release will be in about 9 days. Check out GT Biopharma Basic Forecasting Models to cross-verify your projections.GT Biopharma Related Hype Analysis
Having access to credible news sources related to GT Biopharma's direct competition is more important than ever and may enhance your ability to predict GT Biopharma's future price movements. Getting to know how GT Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how GT Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ARTL | Artelo Biosciences | (0.03) | 8 per month | 0.00 | (0.07) | 7.30 | (8.33) | 41.63 | |
| PTIX | Protagenic Therapeutics | 0.14 | 2 per month | 0.00 | (0.18) | 15.65 | (18.37) | 58.73 | |
| CARM | Carisma Therapeutics | 0 | 4 per month | 8.82 | 0.04 | 17.95 | (14.06) | 56.42 | |
| SLRX | Salarius Pharmaceuticals | (0.02) | 6 per month | 0.00 | (0.19) | 16.00 | (16.92) | 61.05 | |
| WINT | Windtree Therapeutics | 0.00 | 4 per month | 0.00 | (0.19) | 16.67 | (20.00) | 75.00 | |
| PBM | Psyence Biomedical Ltd | (0.11) | 11 per month | 0.00 | (0.22) | 9.96 | (13.79) | 48.52 | |
| SLXN | Biomotion Sciences Ordinary | (0.09) | 5 per month | 0.00 | (0.11) | 15.09 | (9.15) | 37.24 | |
| LIPO | Lipella Pharmaceuticals Common | 0.00 | 1 per month | 0.00 | (0.04) | 17.65 | (21.74) | 94.73 | |
| DRMA | Dermata Therapeutics | (0.50) | 7 per month | 0.00 | (0.09) | 16.18 | (16.23) | 61.86 | |
| REVB | Revelation Biosciences | (0.08) | 7 per month | 0.00 | (0.25) | 6.84 | (10.16) | 35.57 |
GT Biopharma Additional Predictive Modules
Most predictive techniques to examine GTBP price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for GTBP using various technical indicators. When you analyze GTBP charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About GT Biopharma Predictive Indicators
The successful prediction of GT Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as GT Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of GT Biopharma based on analysis of GT Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to GT Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to GT Biopharma's related companies. | 2025 | 2026 (projected) | Payables Turnover | 0.002371 | 0.002253 | Days Of Inventory On Hand | 61.05 | 86.22 |
Pair Trading with GT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with GTBP Stock
Moving against GTBP Stock
| 0.66 | PYC | Physiomics Plc | PairCorr |
| 0.61 | DNLI | Denali Therapeutics | PairCorr |
| 0.6 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.54 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.53 | CMB | Cambium Bio Earnings Call This Week | PairCorr |
| 0.52 | 6C1 | CytomX Therapeutics | PairCorr |
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.